Protagonist Therapeutics (PTGX) Q3 2026 earnings review
Protagonist collects $275 million on approval, but royalties stay unreported
Protagonist, a drug inventor paid by bigger partners, turned a new approval into cash, but its royalty income remains unclear. US regulators approved MIMRYLO, a blood-cancer drug that Takeda sells, and the decision triggered $275 million in payments. Outside those payments, revenue came to $8 million. The company does not say how much of that came from ICOTYDE, the psoriasis pill Johnson & Johnson sells.
| Revenue excluding one-time payments | $7.8M $21.1M last quarter |
|---|---|
| Net income | $220.0M loss of $39.3M a year ago |
| Cash and investments, plus Takeda's October payment | About $1.11B $646.0M at the end of 2025 |
| Research spending outlook | Rising in Q4 at least $46.7M by our math, 13% above Q3 |
⚖️ Verdict: 🟢 Bullish
The story got better because MIMRYLO now earns Protagonist a royalty on every sale, and approval removed the risk of a rejection. The cash also pays for its own pills. One caution: staff received far more new shares than the buyback retired, so the share count still went up.
The question now is how quickly royalties from the two drugs will build. They may soon cover the rising research bill, or starter packs and slow insurance approvals may keep them small for several quarters. Takeda's first MIMRYLO sales and Protagonist's fourth-quarter results will tell.
🐂 Bull Case
MIMRYLO Approval Brought $275 Million and Royalties
MIMRYLO is an injection for polycythemia vera, a rare blood cancer in which the body makes too many red blood cells. Protagonist discovered the drug and ran its main trial, then in April gave Takeda full control of it.
The FDA approved MIMRYLO in late August. That decision triggered a $200 million fee for leaving the cost-sharing deal and a $75 million milestone payment, which Takeda paid in October. In September, the National Comprehensive Cancer Network added the drug to its guidelines as a "Category 1 treatment option" for low- and high-risk patients.
- Revenue booked from the two payments: $266.6 million, with $8.4 million deferred to later quarters
- Royalty rate: 14% to 29% of worldwide sales
- Further milestones on offer: up to $875 million
This matters because Protagonist keeps a royalty that rises with sales while Takeda pays for the launch. But the payments say nothing yet about demand, because Takeda has not published any MIMRYLO sales.
What to watch: Takeda's first MIMRYLO sales figure and the first MIMRYLO royalty in Protagonist's fourth-quarter results. Steady early sales would show that doctors are moving patients onto the new injection.
Cash Reaches About $1.1 Billion After October Payment
Protagonist ended September with $834.6 million in cash and short-term investments. Takeda paid the MIMRYLO approval money in October, after the quarter closed. Adding that sum, the drug inventor holds about $1.1 billion by our math, and it carries no debt.
Operations brought in $146.9 million of cash in nine months, against $94.6 million a year earlier. In its quarterly filing, Protagonist wrote that it does "not currently anticipate a need for additional funding in the near term".
So the group can fund PN-881, its experimental psoriasis pill, and its obesity drugs without selling new stock. But one-time payments supplied most of this cash.
What to watch: cash at year-end, after higher research spending and more buybacks. A balance near $1.1 billion would show interest and royalties covering most running costs.
ICOTYDE Wins Approvals in Europe, Japan and China
ICOTYDE is a daily psoriasis pill that blocks the IL-23 receptor, which drives the inflammation behind the disease. Johnson & Johnson sells it and pays Protagonist royalties of 6% to 10% of sales.
During the quarter, regulators in the European Union, Japan and China approved the pill. In November, J&J said it matched ustekinumab, an established psoriasis drug, in a head-to-head trial, though "statistical superiority was not demonstrated".
Each new country widens the sales base that royalties come from. But matching an older drug, rather than beating it, gives doctors less reason to switch patients who are doing well.
What to watch: an FDA filing for psoriatic arthritis, the next disease J&J is testing. Acceptance of that filing would pay Protagonist $25 million and open a second market.
🐻 Bear Case
Protagonist Does Not Report Its Royalty Income
Chief executive Dinesh Patel said the two partnerships are fueling "an accelerating revenue engine". That engine is royalties: a share of sales of ICOTYDE, J&J's psoriasis pill, and of MIMRYLO, Takeda's blood-cancer drug.
This quarter's figures do not show that engine yet. Outside the approval payments, revenue came to $7.8 million, down from $21.1 million in the second quarter. Protagonist does not split royalties out of that sum, which also includes trial work it did for Takeda.
In its filing, the company wrote that "associated royalty revenue may lag in the near term". It said launches often use "starter packs and bridge programs" while insurers set up payment. That explanation is reasonable, but it leaves Patel's claim resting on sales that outsiders cannot yet see. Fees for Takeda work will shrink too, because Takeda took over most trials in July.
What to watch: whether the fourth-quarter results give a separate royalty figure for ICOTYDE. A figure that fails to climb each quarter would mean the launch runs slower than Patel's words suggest.
Share Count Keeps Rising Despite the New Buyback
In September, the board approved a buyback of up to $300 million. Patel said the program lets Protagonist "return meaningful capital to shareholders".
In its first weeks, the program bought 40,560 shares for $5.8 million. Over the same quarter, staff received 584,120 new shares through stock options and an employee purchase plan.
- New shares issued for each share bought back: about 14
- Average basic share count: 66.4 million, up 4.1% from a year ago
This matters because owners gain from a buyback only when the share count falls. Staff grants still outweigh it, and the average count has risen for four straight quarters.
What to watch: shares bought back in the fourth quarter. Purchases far above September's would show the program can actually cut the share count.
Pipeline Start Dates Keep Moving Later
Protagonist wants its own drugs to follow the two it licensed out: PN-881, a psoriasis pill, and PN-477, an obesity drug that targets three hormone receptors.
The company once planned the first human trial of oral PN-477 for late 2026, and now says the first half of 2027. PN-881's mid-stage trial also moved, from year-end into early 2027.
- Research spending in the third quarter: $41.3 million, below the first two quarters
- Spending on MIMRYLO trials: down 85% as Takeda took over
Partner cash creates value only if the next drugs reach patients. Each delay pushes back the first patient data from Protagonist's own pills, so the business leans on two partners for longer.
What to watch: the start of the PN-881 psoriasis trial, set for early 2027. Another delay would show that the whole schedule, not one program, runs late.
👓 Other Themes
Takeda Now Pays for Remaining MIMRYLO Work
Protagonist's cost-sharing period with Takeda on MIMRYLO ended on July 27. Takeda now runs all US work on the drug, while Protagonist finishes a long-term extension study due to end in early 2027. Those costs "will be fully reimbursed by Takeda", the filing says. The deal therefore no longer counts as a joint arrangement in the accounts.
💲 Other KPIs
Overhead, the cost of running the company outside the labs, rose 23% from a year ago, to $13.7 million. Its growth has quickened in each quarter this year. Hiring drove it, as overhead headcount went from 29 to 38.
Pay in shares rose 36% from a year ago. That growth has picked up from 5% in the first quarter and 29% in the second. It costs no cash, but it adds shares, which helps explain why the count keeps rising.
Interest on the cash pile rose 17% from a year ago, after a 13% drop in the second quarter. Protagonist credits higher average balances. The October payment from Takeda adds to the balance that earns this interest.
🔮 Guidance
Cut. The plan now says only that fourth-quarter research spending will top each earlier 2026 quarter. By our math, that means at least $46.7 million, 13% above the third quarter. The August plan called for a much larger second half, which would now need about $47.5 million. PN-881 trial preparation, drug manufacturing for new programs and hiring drive the rise.
Unchanged. Protagonist still plans a mid-stage, dose-finding trial of PN-881, its once-daily psoriasis pill, early in the first quarter of 2027. The date moved once before: two quarters ago, the plan said year-end. Early tests showed drug levels above target and no serious side effects.
Unchanged. The first human trial of PN-477o, an oral obesity drug that targets three hormone receptors, still starts in the first half of 2027. The date has moved twice; a year ago the plan said late 2026. The company now puts this oral version ahead of the injected one.
Unchanged. Protagonist plans the first human trial of PN-8047, a pill for polycythemia vera, in the first quarter of 2027. The filing says the pill may complement the injected MIMRYLO. Safety studies needed before the trial are under way.
Unchanged. Human testing of PN-458o, an oral obesity drug that targets two hormone receptors, still starts in the second half of 2027. Safety studies needed before the trial are under way.
❓ Key Questions
How much did ICOTYDE royalties earn this quarter?
Protagonist reports royalties inside one line with service fees from Takeda. Without a separate figure, readers cannot tell how J&J's launch of the psoriasis pill is going in its second full quarter on the US market.
When will Takeda publish MIMRYLO sales figures?
MIMRYLO royalties run from 14% to 29% of sales, so the drug could become Protagonist's main income. The first sales number will show how quickly doctors start patients on the injection.
How large will research spending be in 2027?
Next year brings the PN-881 mid-stage trial and three first human trials. A spending range would show how much of the royalty income the pipeline will absorb.
Will buybacks outpace the shares issued to staff?
Staff received about 14 new shares for every share the program bought in the third quarter. Without a pace for purchases, the share count may keep rising.
Does the cash plan through 2028 still stand?
Earlier releases said cash would last through at least the end of 2028. This release dropped that line even though the balance grew. A fresh statement would show how the board weighs buybacks against pipeline spending.